Article Text

Download PDFPDF
Original research
The WOVEN trial: Wingspan One-year Vascular Events and Neurologic Outcomes
  1. Michael J Alexander1,
  2. Alois Zauner2,
  3. Rishi Gupta3,
  4. Amer Alshekhlee4,
  5. Justin F Fraser5,
  6. Gabor Toth6,
  7. Curtis Given7,
  8. Larami Mackenzie8,
  9. Brian Kott9,
  10. Ameer E Hassan10,
  11. Harish Shownkeen11,
  12. Blaise W Baxter12,
  13. R Charles Callison13,
  14. Wengui Yu14
  1. 1 Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
  2. 2 Department of Neurosurgery, Stroke and Neurovascular Center of Central California, Santa Barbara, California, USA
  3. 3 Neuroscience Department, WellStar Medical Group, Marietta, Georgia, USA
  4. 4 Department of Neurology, SSM Health, St. Louis, Missouri, USA
  5. 5 Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA
  6. 6 Cerebrovascular Center, CCF, Cleveland Heights, Ohio, USA
  7. 7 Baptist Health Lexington, Lexington, Kentucky, USA
  8. 8 Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  9. 9 Department of Radiology, MultiCare Health System, Tacoma, Washington, USA
  10. 10 Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA
  11. 11 Central Dupage Health, Winfield, Illinois, USA
  12. 12 Department of Radiology, University of Tennessee, Knoxville, Tennessee, USA
  13. 13 Department of Neurology, Lawnwood Regional Medical Center and Heart Institute, Fort Pierce, Florida, USA
  14. 14 Department of Neurology, University of California Irvine, Irvine, California, USA
  1. Correspondence to Dr Michael J Alexander, Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; michael.alexander{at}


Background Prior studies evaluating the Wingspan stent for treatment of symptomatic intracranial atherosclerotic disease have included patients with a spectrum of both on-label and off-label indications for the stent. The WEAVE trial assessed 152 patients stented with the Wingspan stent strictly by its current on-label indication and found a 2.6% periprocedural stroke and death rate.

Objective This WOVEN study assesses the 1-year follow-up from this cohort.

Methods Twelve of the original 24 sites enrolling patients in the WEAVE trial performed follow-up chart review and imaging analysis up to 1 year after stenting. Assessment of delayed stroke and death was made in 129 patients, as well as vascular imaging follow-up to assess for in-stent re-stenosis.

Results In the 1-year follow-up period, seven patients had a stroke (six minor, one major). Subsequent to the periprocedural period, no deaths were recorded in the cohort. Including the four patients who had periprocedural events in the WEAVE study, there were 11 strokes or deaths of the 129 patients (8.5%) at the 1-year follow-up.

Conclusions The WOVEN study provides the 1-year follow-up on a cohort of 129 patients who were stented according to the current on-label use. It provides a more homogeneous patient group for analysis than prior studies, and demonstrates a relatively low 8.5% 1-year stroke and death rate in stented patients.

  • stent
  • stenosis
  • atherosclerosis
  • intervention
  • stroke

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @GaborTothMD

  • Correction notice Since the online publication of this article, the title has been updated as 'Outcomes' was incorrectly spelt as 'utcomes'.

  • Contributors All the authors contributed to the data collection and manuscript review.

  • Funding The WOVEN Trial was a physician-initiated study without industry or public funding.

  • Disclaimer The WOVEN Trial sites and primary investigator interventionalists included SSM DePaul Medical Center (Ameer Alshekhlee), WellStar Health System (Rishi Gupta), Cedars Sinai Medical Center (Michael J. Alexander), The Cleveland Clinic (Gabor Toth), Multicare Medical Center (Brian Kott), Santa Barbara Cottage Hospital (Alois Zauner), University of Kentucky Medical Center (Justin Fraser), Central Baptist Health (Curtis Given II), Abington (Larami Mackenzie), Valley Baptist Medical Center – Harlingen (Ameer Hassan), Tennessee Interventional Associates (Blaise W. Baxter), Cadence Health Central DuPage (Harish Shownkeen). The research coordinators in the WOVEN study included: Vicki Manoukian, Gabriella Diaz, Janey Barnhart, Ashley Depalmo, Jennifer Isaacs, Laurie Preston, Erin Ross, Linda Breathitt, Kathy Hansen, Michelle Raymond, and Jacquie Johnson.

  • Competing interests MJA, AZ, RG, AEH, BWB, RCC and WY are scientific consultants for Stryker Neurovascular. No industry compensation was provided for this research or the production of this manuscript to any of the investigators.

  • Patient consent for publication Not required.

  • Ethics approval The WOVEN Trial was approved by the Cedars-Sinai institutional review board under identification number STUDY00000379.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. De-identified data access requires institutional review board approval and signed data usage agreement.